Oculis OCS 深 滬
等待開盤 09-08 09:30:00 美东时间
12.17
0.000
0.00%
華盛通- 最 高12.66
- 今 開12.07
- 成交量 12.43万股
- 最 低 11.93
- 昨 收 12.17
- 總市值 7.51亿
- 52周最高 34.475
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 10.52
- 委 比 -35.14%
- 總股本 6173.21万
- 歷史最高 34.475
- 量 比 0.80
- 振 幅 6.00%
- 歷史最低 6.26
- 每 手 1
- 風險率 6.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG has initiated the PIONEER-1 trial to evaluate Privosegtor for optic neuritis (ON), with the first patient treated in the U.S. Privosegtor, a novel neuroprotective agent, showed promising results in the Phase 2 ACUITY trial, leading to FDA Breakthrough Therapy and EMA PRIME designations. The trial aims to assess visual recovery and safety, with potential broader applications in neurology, including acute multiple sclerosis relaps...
08-24 08:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
08-15 00:25
Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $392.150 thousan...
08-07 15:54
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Holding AG reported Q2 2026 results, highlighting progress in its neuro-ophthalmology pivot with Privosegtor advancing in optic neuritis and potential expansion into acute MS relapses following positive FDA feedback. Licaminlimab's PREDICT-1 trial for dry eye disease is on track with over 45% patient enrollment. The company has $282.3 million in cash, providing runway into H2 2029. Upcoming milestones include R&D Day for Privosegtor and to...
08-06 20:05
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Holding AG announced positive FDA pre-IND feedback for Privosegtor in acute multiple sclerosis (MS) relapses. The FDA supports the regulatory pathway and confirms existing data can be used for an IND submission in the fourth quarter of 2026. Privosegtor, a neuroprotective candidate, has shown promise in optic neuritis and aims to address unmet needs in MS relapse treatment. Oculis plans to host an R&D Day later this year to provide further...
08-03 08:00
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 2% on Friday. Shares of Intuitive Surgical Inc (NASDAQ:ISRG) fell sharply in pre-market trading after the company reported second-quarter financial results. Intuitive Surgical reported quarterly earnings of $2.80 ...
07-17 20:02
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference, where management will discuss its late-stage pipeline. Key highlights include Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, targeting a $7B+ market, and Licaminlimab, a topical anti-TNFα for dry eye disease. The Company is well-positioned to achieve value-driving milestones, f...
07-02 08:00
Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1
06-09 16:16
